Outside Director PAIK SOONMYUNG acquires 8,544 shares via paid-in capital increase, raising stake to 0.05%... Limited impact on shareholder value


  • Outside Director PAIK SOONMYUNG acquired 8,544 new shares at 4,860 won per share on May 21, 2026, increasing total holdings from 33,000 to 41,544 shares.
  • Accordingly, the filer's stake rose from 0.04% to 0.05% of total outstanding shares (91,272,269), still negligible.
  • Acquisition price (4,860 won) is about 23% below the base date closing price (6,310 won), which could be interpreted as insider buying at a discount, but the small size limits direct impact on share price.
  • The share issuance is minimal (0.009% of total shares), resulting in negligible dilution for existing shareholders.
  • [AI Comprehensive Analysis]This minor insider purchase signals management confidence, but the scale is too small to significantly affect short-term stock price. Investors should monitor future insider buying and the company's capital-raising plans.

KOSDAQ Filing Information


  • Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders
  • Company: ImmuneOncia Therapeutics (424870)
  • Submission: PAIK SOONMYUNG
  • Receipt: 05-28-2026